Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of Relugolix biological activity fentanyl and propofol or dexmedetomidine infusion. MS-275 clinical trials Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of fentanyl and propofol or dexmedetomidine infusion. Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.
Related Posts
Cide event; Figure 1B) and watching the stimulation be administered (Video
Cide event; Figure 1B) and watching the stimulation be Win 63843 supplement administered (Video event; Figure 1B). Activated voxels were identified using an event-related statistical model representing each of the experimental events, convolved with a canonical hemodynamic response function and mean-corrected. Six head-motion parameters defined by the realignment were added to the model as regressors […]
L, and psychological challenges of HIV illness that men face, seropositiveL, and psychological challenges of
L, and psychological challenges of HIV illness that men face, seropositiveL, and psychological challenges of HIV disease that males face, seropositive ladies also must cope with the stigma and stressors exceptional to their disadvantaged social position (Ickovics Rodin, 992; Mays Cochran, 988). Provided these circumstances, several HIVinfected females might be reluctant to disclose their serostatus. […]
pid volume enhance (left panel) within the absence of an external introduction of an osmotic
pid volume enhance (left panel) within the absence of an external introduction of an osmotic gradient. This cell volume raise promoted TRPV4 activation within the form of TRPV4-mediated currents (middle and ideal panels). Modified from (32) with permission.cIAP-1 Inhibitor web direct Coupling of Cell Volume Modifications to TRPV4 ActivationTRPV4 Gating by means of Mechanical Probing […]